Therapeutic targeting of ATR in alveolar rhabdomyosarcoma

Despite advances in multi-modal treatment approaches, clinical outcomes of patients suffering from PAX3-FOXO1 fusion oncogene-expressing alveolar rhabdomyosarcoma (ARMS) remain dismal. Here we show that PAX3-FOXO1-expressing ARMS cells are sensitive to pharmacological ataxia telangiectasia and Rad3...

Descripción completa

Detalles Bibliográficos
Autores principales: Dorado García, Heathcliff, Pusch, Fabian, Bei, Yi, von Stebut, Jennifer, Ibáñez, Glorymar, Guillan, Kristina, Imami, Koshi, Gürgen, Dennis, Rolff, Jana, Helmsauer, Konstantin, Meyer-Liesener, Stephanie, Timme, Natalie, Bardinet, Victor, Chamorro González, Rocío, MacArthur, Ian C., Chen, Celine Y., Schulz, Joachim, Wengner, Antje M., Furth, Christian, Lala, Birgit, Eggert, Angelika, Seifert, Georg, Hundsoerfer, Patrick, Kirchner, Marieluise, Mertins, Philipp, Selbach, Matthias, Lissat, Andrej, Dubois, Frank, Horst, David, Schulte, Johannes H., Spuler, Simone, You, Daoqi, Dela Cruz, Filemon, Kung, Andrew L., Haase, Kerstin, DiVirgilio, Michela, Scheer, Monika, Ortiz, Michael V., Henssen, Anton G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314382/
https://www.ncbi.nlm.nih.gov/pubmed/35879366
http://dx.doi.org/10.1038/s41467-022-32023-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314382/
https://www.ncbi.nlm.nih.gov/pubmed/35879366
http://dx.doi.org/10.1038/s41467-022-32023-7

Ejemplares similares